Joshua Boger, Ph.D.
Founder, Vertex Pharmaceuticals, and Chair, Biotechnology Industry Organization (BIO)
“I don’t think one researcher’s funding plight means anything much in the scheme of things, but I think my difficult experience is being played out many times over. I hate to think of all the lost opportunities for scientific progress that are going unfunded, and the loss of economic competitiveness that will accrue if these funding trends continue.”
Anne Giersch, Ph.D., Assistant Professor Harvard University and Brigham and Women’s Hospital
Full Report: http://www.brokenpipeline.org/brokenpipeline.pdf